Moderna gained over 2% and reached record high

(Aug 5) Moderna beat on income and revenue in its Q2 earnings. Moderna's COVID vaccine shows 93% effectiveness six months after second dose

Moderna says that its COVID-19 vaccine is 93% effective six months after the second dose.

That's just one percentage point lower than the 94% effectiveness reported in its initial clinical trial that led to the vaccine's Emergency Use Authorization.

Moderna said the sustained efficacy is based on a final analysis of the phase 3 COVE study. The company made the announcement during this morning's Q2 2021 earnings call presentation.

However, the company said it expects antibody levels created by the vaccine to eventually wane, making booster shots likely.

CEO Stephane Bancel also said Moderna will not manufacture more than the 800M to 1B doses already planned this year because of capacity constraints and is not taking additional orders for deliveries this year.

Moderna beat on income and revenue in its Q2 earnings.